KALA BIO, Inc.

Contributing Author

Recent Articles by KALA BIO, Inc.

Jul-09	KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) KALA GlobeNewswire
Jul-07	KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) KALA GlobeNewswire
May-29	KALA BIO to Present at Jefferies Global Healthcare Conference KALA GlobeNewswire
May-14	KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update KALA GlobeNewswire